https://ki.se RSS News Listing https://news.ki.se/nextgennk-at-the-inauguration-of-karolinska-atmp-center NextGenNK Director Hans-Gustaf Ljunggren presented on NK cell–based immunotherapies during the inauguration of the Karolinska ATMP Center on August 25, 2025, sharing experiences from past and upcoming clinical studies. Tue, 26 Aug 2025 13:08:45 +0200 https://news.ki.se/nextgennk-and-ccrm-nordic-mini-symposium Advanced Medicinal Therapy Products, ATMP, span broadly over medical fields and the aim of this symposium is to enhance networking within ATMP and to get a flavor of academic and commercial development of ATMPs in Stockholm and Sweden. NextGenNK and CCRM Nordic are inviting you to a mini-symposium with the focus on ATMP on January 22, 2025. Tue, 10 Dec 2024 13:09:03 +0100 https://news.ki.se/paths-taken-towards-nk-cell-mediated-immunotherapy-of-human-cancer-a-personal-reflection Here, Center Director Hans-Gustaf Ljunggren present some personal recollections and reflections of research in the field of NK cells and work conducted in his laboratory over three decades, leading up towards the current utilization of NK cells in the context of human cancer immunotherapy. Fri, 25 Mar 2022 13:35:07 +0100 https://news.ki.se/learn-the-basics-of-advanced-therapy-medicinal-products What do you know about ATMPs? Equip yourself for the future – learn the basics of Advanced Therapy Medicinal Products (ATMP). Join in and take the Swedish healthcare into the future! Wed, 16 Jun 2021 13:21:17 +0200 https://news.ki.se/nextgennk-at-cell-gene-therapy-2021 Hans-Gustaf Ljunggren, Director, will participate in the digital event - Cell & Gene Therapy 2021, May 18-19. Hans-Gustaf will present one of the Competence Center’s projects - Autologous NK Cells as Consolidation Therapy in Multiple Myeloma. Fri, 16 Apr 2021 16:02:51 +0200 https://news.ki.se/mini-symposium-frontlines-in-nk-cell-cancer-research-and-immunotherapy The symposium is a joint mini symposium between the NextGenNK partners Karolinska Institutet and Sanofi. Wed, 31 Mar 2021 15:33:27 +0200 https://news.ki.se/four-nextgennk-partners-join-forces-in-a-phase-ii-study-in-multiple-myeloma XNK Therapeutics AB (“XNK”) has entered into a joint Phase II clinical study to treat patients with multiple myeloma using XNK’s drug candidate in combination with Sanofi’s anti-CD38 antibody Sarclisa (isatuximab) Wed, 10 Mar 2021 16:05:40 +0100 https://news.ki.se/nextgennk-at-allogeneic-cell-therapies-summit-2021 Karl-Johan Malmberg, co-director of NextGenNK will present his research and the Competence Center at the digital event - Allogeneic Cell Therapies Summit 2021, May 17-19. The meeting is focused on the clinical and commercial development of engineered allogeneic cell therapies and innovating off-the shelf therapies to benefit patients in need. Tue, 01 Dec 2020 14:57:46 +0100 https://news.ki.se/nextgennk-at-innate-killer-summit-2021 The Directors of NextGenNK will present their research and the Competence Center at the digital event - Innate Killer Summit 2021, March 23-25. The meeting will focus on NK cell-based immunotherapies and their clinical translation. Mon, 31 Aug 2020 15:56:38 +0200 https://news.ki.se/nextgennk-interacts-with-camp NextGenNK sets out to deepen its interactions with health care units. Activities, when applicable, will be integrated with the Vinnova funded CAMP, that focuses specifically on GMP-bioprocess development, production and distribution logistics. Fri, 29 May 2020 14:47:01 +0200 https://news.ki.se/first-collaboration-between-partners-in-the-nextgennk-competence-center Avectas and Vycellix Announce Collaboration to Advance Next-Generation Solutions for the Optimized Manufacture of Cell & Gene Therapies. NextGenNK catalyzed interaction among its industrial partners to advance NK cell-based immunotherapies Wed, 25 Mar 2020 14:50:20 +0100